Historically studied, honestly modest
Kwai is a piece of garlic-research history. Its standardized dried-garlic-powder tablets (the LI-111/Kwai formulation) were the intervention in a large share of the 1980s–1990s clinical trials that put garlic on the cardiovascular map. That heritage is a genuine strength — you are buying the exact form that was studied.
But honesty cuts both ways: many of those same trials, especially the later, better-controlled ones, found only small or statistically non-significant lipid changes at the 300 mg dose. The tablet is coated roughly 60x for odor control and standardized to about 1800 mcg allicin yield. It is a legitimate, well-characterized option that simply carries a more sober evidence record than its historical fame implies.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Garlic guide →Standardized dried garlic powder in a multi-coated tablet. Well-characterized in the literature, but powder tablets depend on alliinase surviving digestion, and coating primarily addresses odor rather than guaranteeing allicin delivery.
300 mg standardized powder yielding ~1800 mcg allicin — the exact dose used in landmark trials, which is a documentation advantage even though the dose is modest by modern high-allicin standards.
Long-standing branded formulation with historical QC pedigree, but no modern prominent NSF/USP seal or public batch COA on the current SKU.
The ~60x coating is designed for odor control and the one-a-day format is easy to tolerate. Standard garlic antiplatelet caution applies.
Around $15 for 100 one-a-day tablets is reasonable for a named, historically-studied formulation, though the modest dose caps the value ceiling.
“This is the garlic form used in major clinical trials”
The Kwai/LI-111 standardized garlic powder was the intervention in numerous 1980s–1990s randomized trials referenced across garlic meta-analyses, making its clinical characterization well documented.
“It reliably lowers cholesterol at 300 mg”
Better-controlled later trials (e.g., Isaacsohn 1998; Neil 1996) using the Kwai powder found small or non-significant lipid changes, and meta-analyses classify garlic's cholesterol effect as modest and baseline-dependent.
“The coating controls garlic odor”
The heavy multi-layer coating delays release and reduces immediate odor for many users, though powder-based tablets still produce more breath odor than aged garlic extract.
Kwai's fame rests on being studied, not on being the strongest performer. Several of the most rigorous trials using this exact powder reported disappointing lipid results, which is part of why the field shifted toward aged extract and higher-allicin enteric forms for blood pressure specifically.
At ~1800 mcg allicin yield, Kwai delivers less than the 5000 mcg enteric tablets. That is not necessarily worse for BP (effects plateau), but it means you are not buying a high-potency product — you are buying a well-documented standard dose.
Kwai is worth considering if you value buying the exact form that clinical research studied and want reliable odor control. Just go in clear-eyed: the very trials that made it famous produced modest, sometimes null lipid results. For a stronger evidence base choose Kyolic AGE; for higher allicin choose NOW.
Pooled trials, several using standardized garlic powder, showed a modest systolic BP reduction of roughly 7–8 mmHg versus placebo.
Garlic powder preparations lowered cholesterol only modestly and mainly in people with elevated baseline levels using it for two months or longer.
